ANPs drug is much further down the road. And in comparison has far less risk and is years closer to being marketable. It also already has ODD and a prv. I would hope upfront payment to be larger because of that for DMD.
LC and LG, if done as separate deals, could be like this.
The main difference is, they have a deal and we dont.
Controlling Cd49 is proving to have a far reach into many inflammation ailmsnts. We dont want it under valued.
For General Information, page-1459
-
- There are more pages in this discussion • 2,068 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
